Company Profile

Hangzhou Tigermed Consulting Co., Ltd（stock symbol: 300347） is a leading Contract Research Organization (CRO) in China dedicated to provide professional full clinical trial services. Since inception in 2004, Tigermed has been committed to accelerating medical product development with costs efficiency and quality.

Headquartered in Hangzhou, Tigermed operates 33 subsidiaries, 63 offices across China and 12 overseas offices in Hong Kong China, Taiwan China,USA, Switzerland, Canada, Korea, Australia, Japan, Malaysia, Singapore, India and Romania with over 3600 full time staffs. Tigermed has serviced more than 600 local and global clients in the conduct of over 1060 clinical trials. Tigermed is recognized as “The Innovative Clinical CRO” in China，owning to our involvement of over 150 innovative drugs.

For more information about Tigermed, please visit

http://www.tigermed.net

Tigermed Coverage

63offices in China mainland

12 overseas offices – Hong Kong China, Taiwan China, Korea, Japan, Malaysia, Singapore, India,Australia, Canada, USA, Switzerland, Romania

Company Profile

Human Metabolome Technologies (HMT) is a Japan-based biotechnology company developing capillary electrophoresis mass spectrometry (CE-MS) based metabolomics technologies and solutions to drive drug discovery, diagnosis, and food production. Their research and development methodology are at the heart of an emerging field of metabolomics and systems biology.

HMT can identify more than 1,000 species of metabolites by the metabolome analysis technology using CE-MS. In addition, HMT developed an original software analysis platform along with the measuring technologies, such as CE-MS, LC-MS, and MS/MS, that they have newly developed for the realization of metabolome analysis. Furthermore, they aim to develop a faster metabolome analysis technology with higher sensitivity and higher efficiency in collaboration with the Institute for Advanced Biosciences (IAB), Keio University.

HMT’s primary business aims to provide complete solutions for metabolome analysis in drug design, diagnostic technology, and food production, using a wide range of targets including human and animal samples — They are a full service metabolomic provider.

HMT’s metabolomics approach is based on a notable history of academic research and scientific leadership. One of the co-founders, Professor Masaru Tomita, Ph.D., Director of IAB, is a recognized leader in computational biology and metabolomics who has carried out research on computer simulations of cellular metabolism for over 10 years. Professor Tomita co-founded HMT with Tomoyoshi Soga, Ph.D., Professor at IAB, who established the cutting-edge technology of CE-MS based metabolome analysis, the basis of HMT’s core technology. Founded in July 2003, HMT successfully operates on a revenue-based growth model. The company has been awarded government funding from the New Energand Industrial Technology Development Organization (NEDO). HMT has also established a number of partnerships, including Agilent Technologies, Inc., Mizkan Group Corporation, Ajinomoto, Co. Inc., and Mitsubishi Pharma Corporation.

For more information about Tigermed, please visit

For more information about HMT, please visit http://www.tigermed.net

Company Profile

BioVinc LLC is a privately owned R&D company located in Los Angeles, California. It has an extraordinary portfolio of IP and development products which collectively address a product market of over $1-2 billion per year. The portfolio is based on its core expertise in bisphosphonate research that has led to a platform technology to leverage selective bone targeting properties for the discovery of improved therapeutics and diagnostics for the management of a variety of bone diseases. New small molecule leads have been identified and advanced toward a preventative therapy for osteonecrosis of the jaw in oral surgery patients, and bone selective antibiotics for the treatment of infectious bone disease, Other advances are underway towards re-purposed drugs for rheumatoid arthritis, osteoporosis, and bone cancers; and optical and nuclear diagnostic imaging probes, including a superior PET scan technology for the replacement of Technetium-99m Bone Scan imaging.

In addition, BioVinc has also commercialized many new fluorescent molecular probes that target bone for research use which can be ordered on this website. The probes are derived from nitrogen-containing bisphosphonates such as zoledronate (ZOL)and, risedronate (RIS) including lower bone affinity analogues conjugated with a wide choice of popular visible and near infrared fluorescent dyes to address different imaging needs in bone related research including bone biology, bone pharmacology, dental, cochlear, and cardiovascular research. Custom “mix-and-match” bisphosphonate-dye pairings are also available on request. By providing both off-the-shelf imaging probes and individually tailored probe design services, BioVinc can help with all aspects of your research needs. The probes have already been used in diverse imaging studies including research on bone metabolism, cancer, and dental conditions.

For more information about BioVinc, please visit

For more information about HMT, please visit http://www.biovinc.com